Remedial Health
+101%
est. 2Y upside i
B2B E-commerce & Fintech platform for Pharmacies & Hospitals in Africa
Rank
#570
Sector
Healthtech, Fintech, Supply Chain
Est. Liquidity
~6Y
Data Quality
Data: LowRemedial Health is a credible but highly uncertain Series A bet in a real, large market — do not count on equity as a material near-term compensation component.
Last updated: May 13, 2026
Remedial Health achieves breakout growth in Nigeria and expands to 3+ African markets, closing a Series C at $400M+ by 2028 and capturing meaningful share of a $16.6B TAM growing at 23.4% annually. This represents a ~4-5x step-up from the estimated $80M post-Series A valuation, driving substantial common equity gains after clearing $16.4M in preferences.
Consistent with its FT fastest-growing healthtech recognition, the company closes a Series B at $150–180M by 2028, roughly a 2x step-up from estimated current valuation. Competitive pressure from Drugstoc and Axmed, combined with Nigeria macro headwinds, limits faster geographic expansion.
Naira devaluation, a tight VC fundraising environment for African startups, or inability to demonstrate profitable unit economics forces a flat or down Series B — or delays it past 2028. With $16.4M in senior liquidation preferences against an already uncertain valuation, common stock holders face near-total dilution.
Preference Stack Risk
highFunding Intensity
21%$16.4M in total funding sits senior to common stock against an estimated $60–80M post-Series A valuation, implying a ~20–27% liquidation preference overhang that common holders must clear before participating in proceeds.
Dilution Risk
highAs a Series A company requiring Series B, C, and likely D rounds before any liquidity event, employees should model 45–60%+ cumulative dilution to their current grant.
Secondary Liquidity
noneNo secondary market exists for early-stage African startup equity; realizing any value requires an IPO or acquisition, expected no sooner than 5–7 years from today.
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Remedial Health's data — designed to show you've done your homework.
- 1
“What is your current ARR and trailing YoY revenue growth rate, and what specific milestone — revenue, GMV, or geography — triggers your Series B raise?”
- 2
“How has the Naira devaluation since 2023 affected your unit economics — do you price transactions and credit facilities in USD or local currency, and what is your gross margin on the fintech book?”
- 3
“What is the current 409A valuation per share, the fully diluted share count, and what percentage of the company would my proposed equity grant represent after accounting for the option pool?”
Community
Valuation Sentiment
Our model estimates +101% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.